Table 2.

Case series/case studies included in the narrative review (N = 4).

Author, Year, and Country	Sample Size	Assessment Tool	Main Findings	Study’s Limitations
Oguchi et al., 2023, Japan [38].	One young male patient with schizophrenia, aged 20 years old.	No specified, qualitative interview	The patient developed post-psychotic depression, including despair, overwhelming loss, humiliation, and suicidal ideation, during treatment with paliperidone. He was switched to lurasidone 40 mg monotherapy.	Case report
Ricci et al., 2023, Italy [46].	One young male patient with schizophrenia, aged 19 years old.	Positive and Negative Syndrome Scale (PANSS) Clinical Global Impression–Severity Scale (CGI-S) Montgomery–Asberg Rating Scale (MADRS)	19-year-old male patient with first-episode psychosis (FEP) and predominant depressive symptoms. Remarkable clinical and functional improvement was observed 3 months after the beginning of lurasidone treatment. The patient’s depressive symptoms disappear with a dramatic reduction of psychotic ones, with good tolerance of the drug and without adverse effects. Lurasidone seems to be a promising treatment option for FEP with predominant depressive symptoms.	Case report
Olivola et al., 2023, Italy [47].	Four patients treated with clozapine who were diagnosed with treatment-resistant schizophrenia.	Positive and Negative Syndrome Scale (PANSS) Udvalg for Kliniske Undersøgelser Side Effect Rating Scale (UKU-SERS)	All patients achieved a significant reduction of both positive and negative symptoms, with no significant adverse effects to be reported.	Case series
Ricci et al., 2022, Italy [39].	Four patients experienced their first cannabis-induced psychotic episode.	Unspecified	Lurasidone also appears to be effective in other symptom domains related to schizophrenia, such as depressive symptoms.	Case series